10:52:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-10-30 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 Årsstämma 2024
2024-04-24 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-26 X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2023-01-12 Extra Bolagsstämma 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-05 Kvartalsrapport 2022-Q2
2022-05-30 Kvartalsrapport 2022-Q1
2022-05-23 X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-12 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-14 X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-11 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-11-08 Extra Bolagsstämma 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-13 X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-16 X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-11-03 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-02-09 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga patienttillstånd inom kroniska inflammatoriska sjukdomar, samt diverse ledskador. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2024-05-31 07:30:00

SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter of 2024.

“The first quarter of 2024 was incredibly busy, but I feel confident that the company now has the right team and plan in place to put SynAct back on the right path,” said Jeppe Øvlesen, CEO of SynAct.

January – March 2024

  • The Group’s net sales amounted to SEK 0 (0) thousand.
  • Operating expenses amounted to SEK 25,706 (58,248) thousand, a decrease of 56%.
  • The Group’s loss after tax amounted to SEK 24,906 (49,878) thousand.
  • The Group’s earnings per share before and after dilution amounted to SEK -0.70 (-1.59).
  • Cash flow from operating activities amounted to SEK -11,189 (-30,472) thousand.
  • Cash flow from financing activities amounted to SEK -154 (-246) thousand.
  • Cash flow for the period amounted to SEK -11,343 (-30,482) thousand.
  • Cash and cash equivalents at the end of the period amounted to SEK 51,553 (78,214) thousand.

Significant events during the period

  • Jan 30 - SynAct expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors.
  • Feb 1 - SynAct appoints Kirsten Harting as Chief Medical Officer.
  • Feb 7 - Notice of extraordinary general meeting in SynAct Pharma AB. Upon request by >10% of the shareholders, an extra general meeting has been set to March 20, 2024.
  • Feb 22 - SynAct announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis.
  • Mar 10 - SynAct announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis.
  • Mar 20 - The Extraordinary General Meeting resolved, in accordance with the proposal to elect a new Board for the period until the end of the 2024 Annual General Meeting. The Board of Directors appointed Jeppe Øvlesen as CEO of SynAct.
  • Mar 22 - SynAct comments on ownership changes among senior executives.
  • Mar 26 - SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK.
  • Mar 27 - SynAct Pharma AB has successfully completed the bookbuilding procedure – directed issues provides the company with a total of up to 49.2 MSEK and sends out notice of extraordinary general meeting in SynAct Pharma AB.

Significant events after the end of the period

  • Apr 30 - SynAct Pharma AB announces that the number of shares and votes has increased by 5,725,484 as a result of the directed share issues resolved upon by the extraordinary general meeting on April 24, 2024.

For further information about SynAct Pharma AB, please contact:
Jeppe Øvelsen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67 
Mail: joo@synactpharma.com
 
Björn Westberg
CFO, SynAct Pharma AB 
Phone: +46 703 33 91 23
Email: BWE@synactpharma.com